Head-to-head evidence
SHR-1707 vs Trontinemab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: Amyloid-beta (monoclonal antibody) · full Alzheimer's Disease pipeline
SHR-1707
Developed by Jiangsu Hengrui Pharmaceuticals
NCT05681819 · Phase 1 · completed
The trial randomized 33 participants to SHR-1707 or placebo with triple-blinding, a design able to isolate a genuine drug effect, but its primary outcomes were safety measures rather than a cognitive or functional efficacy endpoint, and results have not yet been posted, so no effect on Alzheimer's disease could be established from this record.
Trontinemab
Developed by Roche
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: July 2027 · NCT04639050 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: SHR-1707's landscape · Trontinemab's landscape